Phase III PREVENT-19 study of Novavax recombinant nanoparticle protein-based COVID-19 vaccine (NVX-CoV2373) meets primary endpoint

This multicentre study (n=29,960) met its primary endpoint, demonstrating 90.4% efficacy (63 COVID-19 cases in placebo group and 14 in vaccine group) and its key secondary endpoint demonstrating 100% efficacy against variants "not considered Variants of Concern/Interest."

Source:

Biospace Inc.